 |
U.S. melanoma therapeutics market
revenue by therapy, 2014 - 2025 (USD million)
The global melanoma therapeutics market is expected to reach USD 12.4
billion by 2025, according to a new report by Grand View Research, Inc.
Increasing incidence of chronic diseases such as melanoma, skin cancer, and
skin allergies is an important driver of the market.
According to CDC, over 71,943 people were affected by melanoma in 2013.
The American Cancer Society estimates that this number will go up to 87,100 in
2017, thus highlighting the need for melanoma drugs over the forecast period.
Increasing number of FDA approvals and introduction of novel
therapeutics with enhanced efficacy are also anticipated to present growth
opportunities. Within a period of 6 years, i.e., from 2011 to 2016, around
eight biologics have been approved for the treatment of this disease, which
include Opdivo, Yervoy, Cotellic, Zelboraf, Keytruda, Mekinist, Tafinlar, and
Imlygic.
Companies are undertaking various R&D activities to find new
indications for existing products and development of innovative molecules. For
instance, in September 2014, the U.S. FDA approved patented drug Keytruda
(Merck & Co., Inc.) to treat metastatic melanoma, thereby extending the
therapeutic application of its product. This drug was initially approved for
treatment of non-small cell lung cancer.
Furthermore, many pharmaceutical companies in the U.S., Europe, and Asia
Pacific are focusing on development of new biologics. For instance, in March
2017, Daiichi Sankyo Company, Limited announced a collaborative drug discovery
project—Take a New challenge for Drug discovery (TaNeDS)—to facilitate new drug
development through collaborations. Moreover, it entered into a strategic
research collaboration with AgonOX, Inc. to develop new immunotherapy drugs for
the immuno-oncology segment. Approval of novel products over the forecast
period is anticipated to boost market growth.
Full
Research Report On melanoma therapeutics market Analysis:
Further Key Findings From the Study Suggest:
·
Targeted therapy segment is expected to
show lucrative growth owing to benefits such as low adverse effects and higher
efficiency
·
Branded drugs held a dominant share of the
industry because of patent exclusivity
·
Biologics, such as Opdivo and Cotellic, are
expected to exhibit lucrative growth over the forecast period owing to increase
adoption and advantages such improved therapeutic effects
·
The patent for Yervoy will expire in 2022
in the U.S. and in 2020 in Europe. This is expected to provide growth
opportunities for new market entrants
·
Asia Pacific is expected to exhibit
lucrative CAGR over the forecast period
·
Key market players are increasing R&D
efforts for discovery and development of novel drugs for the treatment of
melanoma
View More Reports
Of This Category By Grand View Research At:
Grand View Research has segmented the melanoma therapeutics market on
the basis of therapy, drugs, and region:
Melanoma Therapeutics Therapy
Outlook (Revenue, USD Million, 2014 - 2025)
·
Chemotherapy
·
Immunotherapy
·
Targeted Therapy
·
Radiation Therapy
Melanoma Therapeutics Drugs
Outlook (Revenue, USD Million, 2014 - 2025)
·
Opdivo
·
Yervoy
·
Mekinist+Tafinlar
·
Keytruda
·
Cotellic
·
Zelboraf
·
Imlygic
·
Generics
Melanoma Therapeutics
Regional Outlook (Revenue, USD Million, 2014 - 2025)
·
North America
o U.S.
o Canada
·
Europe
o Germany
o UK
·
Asia Pacific
o Japan
o China
o India
·
Latin America
o Brazil
o Mexico
·
MEA
o South Africa
Access Full Press Release of this Report: https://www.grandviewresearch.com/press-release/global-melanoma-therapeutics-market
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more information: https://www.grandviewresearch.com/
No comments:
Post a Comment